Top

World Journal of Urology

Published in:

01-04-2014 | Original Article

Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer

Authors: D. M. Bolton, A. Ta, M. Bagnato, D. Muller, N. L. Lawrentschuk, G. Severi, R. R. Syme, G. G. Giles

Published in: World Journal of Urology | Issue 2/2014

Abstract

Objectives

To evaluate the temporal relationship between interval to biochemical recurrence (BCR) following radical prostatectomy (RP) and prostate cancer-specific mortality (PCSM).

Patients and methods

The study comprised of 2,116 men from the Victorian Radical Prostatectomy Register, a whole-of-population database of all RPs performed between 1995 and 2000 in Victoria, Australia. Follow-up prostate-specific antigen and death data were obtained via record linkage to pathology laboratories and the Victorian Registry of Births, Deaths and Marriages. Poisson regression models with PCSM as the outcome were fit to the data. Models included age at surgery, Gleason score and tumour stage as covariates.

Results

Median post-surgery and post-BCR follow-up was 10.3 and 7.5 years, respectively. 695 men (33 %) experienced BCR during follow-up, of which 82 % occurred within 5 years of RP; 66 men died from prostate cancer. Men with combined high Gleason sum (≥4 + 3) and extra-prostatic (≥pT3a) disease had substantially increased mortality rate with early BCR, while those experiencing BCR after a longer interval had significantly lower mortality. Men with combined low Gleason sum (≤3 + 4) and organ-confined disease (≤pT2c) risk disease were not at any substantial risk of death in this time frame regardless of timing of BCR following RP.

Conclusions

This study evaluates the temporal relationship between BCR and PCSM using a whole-of-population cohort of men treated with RP. Men with low-risk features of prostate cancer at time of RP have low mortality even if they experience early BCR. This subgroup may be counselled regarding their favourable long-term prognosis.

Stamey TA, Yang N, Hay AR et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909–916PubMedCrossRef

Han M, Partin AW, Zahurak M et al (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–523PubMedCrossRef

Porter CR, Kodama K, Gibbons RP et al (2006) 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 176:569–574PubMedCrossRef

Roehl KA, Han M, Ramos CG et al (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172:910–914PubMedCrossRef

Boorjian SA, Karnes RJ, Crispen PL et al (2010) The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol 183:1003–1009PubMedCrossRef

Lodde M, Harel F, Lacombe L et al (2008) Substratification of high-risk localised prostate cancer treated by radical prostatectomy. World J Urol 26:225–229PubMedCrossRef

Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 5(281):1591–1597CrossRef

Ward JF, Blute ML, Slezak J (2003) The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170:1872–1876PubMedCrossRef

Isbarn H, Wanner M, Salomon G et al (2010) Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 106:37–43PubMedCrossRef

10.

Stephenson AJ, Kattan MW, Eastham JA et al (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 10(27):4300–4305CrossRef

11.

Antonarakis ES, Feng Z, Trock BJ et al (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 109:32–39PubMedCentralPubMedCrossRef

12.

Freedland SJ, Humphreys EB, Mangold LA et al (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433–439PubMedCrossRef

13.

Freedland SJ, Humphreys EB, Mangold LA (2006) Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176:1404–1408PubMedCrossRef

14.

Caire AA, Sun L, Ode O et al (2009) Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology 74:643–647PubMedCrossRef

15.

Amling CL, Blute ML, Bergstralh EJ et al (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164:101–105PubMedCrossRef

16.

Loeb S, Feng Z, Ross A et al (2012) Can we stop prostate specific antigen testing 10 years after radical prostatectomy? J Urol 186:500–505CrossRef

17.

Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101PubMedCrossRef

18.

Johansson J-E, Andren O, Andersson SO et al (2004) Natural history of early, localized prostate cancer. JAMA 291:2713–2719PubMedCrossRef

19.

Bolton D, Severi G, Millar JL et al (2009) A whole of population-based series of radical prostatectomy in Victoria, 1995 to 2000. Aust N Z J Public Health 33:527–533PubMedCrossRef

20.

Trock BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 18(299):2760–2769CrossRef

21.

Eggener SE, Scardino PT, Walsh PC et al (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185:869–875PubMedCrossRef

22.

Klotz L, Zhang L, Lam A et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131PubMedCrossRef

23.

van den Bergh RCN, Vasarainen H, van der Poel HG et al (2010) Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int 105:956–962PubMedCrossRef

24.

Walz J, Chun FKH, Klein EA et al (2009) Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 181:601–607 (discussion 7–8)PubMedCrossRef

25.

Mohler J, Bahnson RR, Boston B et al (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8:162–200PubMed

26.

Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71PubMedCrossRef

27.

Ahove DA, Hoffman KE, Hu JC et al (2009) Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?—implications for a risk-adapted follow-up strategy. Urology 76:1201–1205CrossRef

28.

Tollefson MK, Blute ML, Rangel LJ et al (2011) Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. J Urol 184:925–929CrossRef

Title: Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer
Authors: D. M. Bolton
A. Ta
M. Bagnato
D. Muller
N. L. Lawrentschuk
G. Severi
R. R. Syme
G. G. Giles
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 2/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1125-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer

Abstract

Objectives

Patients and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2014

Prostate cancer detection with real-time elastography using a bi-plane transducer: comparison with step section radical prostatectomy pathology

A learning curve assessment of real-time sonoelastography of the prostate

Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study

Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival

Midterm oncological outcome and clinicopathological characteristics of anterior prostate cancers treated by endoscopic extraperitoneal radical prostatectomy

Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation